Literature DB >> 14680079

Cytokines and dietary energy restriction in stable chronic obstructive pulmonary disease patients.

I Godoy1, A O Campana, R R C Geraldo, C R Padovani, S A R Paiva.   

Abstract

Tumour necrosis factor (TNF)-alpha has been found to be increased in malnourished chronic obstructive pulmonary disease (COPD) patients; however, the main cause of this phenomenon remains undetermined. In normal subjects, TNF-alpha production may be induced by dietary energy deprivation. The aim of this study was to investigate if stable COPD patients present alterations of inflammatory mediators after 48 h of dietary energy restriction. Fourteen COPD patients were admitted to the hospital while receiving an experimental diet with an energy content of approximately one-third of their energy needs. Clinical evaluation, nutritional assessment and serum levels of interleukin (IL)-6, TNF-alpha and C-reactive protein, and secretion of TNF-alpha by peripheral blood monocytes were assessed on admission and after the experimental diet. For reference values of the laboratory parameters, blood was collected from 10 healthy, elderly subjects. COPD patients showed significantly higher serum concentrations of IL-6 than control subjects, however, the experimental diet was not associated with statistically significant changes in the inflammatory mediators. The findings of this study, although preliminary because of the limited degree and duration of the energy restriction, suggest that the elevated levels of tumour necrosis factor-alpha, previously described in undernourished or weight-losing chronic obstructive pulmonary disease patients, may not be linked to a decrease of dietary energy intake.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14680079     DOI: 10.1183/09031936.03.00025303

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  8 in total

1.  Serum interleukins 6 and 8 in mild and severe asthmatic patients, is it difference?

Authors:  Javad Ghaffari; Ali Reza Rafiei; Abolghasem Ajami; Mohammadreza Mahdavi; Bahareh Hoshiar
Journal:  Caspian J Intern Med       Date:  2011

2.  Diaphragm dysfunction in chronic obstructive pulmonary disease.

Authors:  Coen A C Ottenheijm; Leo M A Heunks; Gary C Sieck; Wen-Zhi Zhan; Suzanne M Jansen; Hans Degens; Theo de Boo; P N Richard Dekhuijzen
Journal:  Am J Respir Crit Care Med       Date:  2005-04-22       Impact factor: 21.405

3.  Smoking status and tumor necrosis factor-alpha mediated systemic inflammation in COPD patients.

Authors:  Suzana E Tanni; Nilva Rg Pelegrino; Aparecida Yo Angeleli; Camila Correa; Irma Godoy
Journal:  J Inflamm (Lond)       Date:  2010-06-09       Impact factor: 4.981

4.  Association between tumor necrosis factor-α and chronic obstructive pulmonary disease: a systematic review and meta-analysis.

Authors:  Yang Yao; Jing Zhou; Xin Diao; Shengyu Wang
Journal:  Ther Adv Respir Dis       Date:  2019 Jan-Dec       Impact factor: 4.031

Review 5.  Association of chronic obstructive pulmonary disease and obstructive sleep apnea consequences.

Authors:  Carlos Zamarrón; Vanesa García Paz; Emilio Morete; Felix del Campo Matías
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

6.  Systemic inflammation in COPD in relation to smoking status.

Authors:  Danielius Serapinas; Andrius Narbekovas; Jonas Juskevicius; Raimundas Sakalauskas
Journal:  Multidiscip Respir Med       Date:  2011-08-31

7.  Diaphragm adaptations in patients with COPD.

Authors:  Coen A C Ottenheijm; Leo M A Heunks; Richard P N Dekhuijzen
Journal:  Respir Res       Date:  2008-01-24

8.  Medicinal clays improve the endurance of loaded inspiratory muscles in COPD: a randomized clinical trial of nonpharmacological treatment.

Authors:  Simonetta Baldi; Gian Domenico Pinna; Claudio Bruschi; Fabrizio Caldara; Roberto Maestri; Elena Dacosto; Antonella Rezzani; Ermanno Popovich; Ezio Bellinzona; Paola Crotti; Silvia Montemartini; Claudio Fracchia
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-10-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.